Tenax Therapeutics (TENX) director awarded 30,000 new stock options

Rhea-AI Filing Summary

Tenax Therapeutics director June Sherie Almenoff reported a new stock option grant and her current equity holdings in a Form 4 filing. On January 9, 2026, she was granted a stock option for 30,000 shares of common stock at an exercise price of $13.30 per share. This option becomes exercisable on January 9, 2027 and expires on January 9, 2036, and was reported as held directly.

The filing also lists previously awarded stock options held directly, covering 100,000 shares (exercisable from December 10, 2025 to December 10, 2034), 80,000 shares (exercisable from July 1, 2026 to July 1, 2035), and two very small option positions of 4 shares each. In addition, 1,993 shares of common stock are reported as held indirectly through Meadowlark Management, LLC, with a statement that Almenoff disclaims beneficial ownership except to the extent of her pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almenoff June Sherie

(Last) (First) (Middle)

101 GLEN LENNOX DRIVE SUITE 300

(Street)

CHAPEL HILL NC 27517

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TENAX THERAPEUTICS, INC. [ TENX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								1,993	I	By Meadowlark Management, LLC(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.3	01/09/2026		A		30,000		01/09/2027	01/09/2036	Common Stock	30,000	$0	30,000	D
Stock Option (right to buy)	$3,200							06/10/2022	06/10/2031	Common Stock	4		4	D
Stock Option (right to buy)	$992							06/09/2023	06/09/2032	Common Stock	4		4	D
Stock Option (right to buy)	$5.94							12/10/2025	12/10/2034	Common Stock	100,000		100,000	D
Stock Option (right to buy)	$5.75							07/01/2026	07/01/2035	Common Stock	80,000		80,000	D

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

	/s/ S. Halle Vakani, as Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TENX director June Sherie Almenoff report?

June Sherie Almenoff, a director of Tenax Therapeutics, reported receiving a stock option grant for 30,000 shares of common stock on January 9, 2026, at an exercise price of $13.30 per share, exercisable beginning January 9, 2027 and expiring January 9, 2036.

How many Tenax Therapeutics options does June Sherie Almenoff hold after this Form 4?

After the reported grant, June Sherie Almenoff’s directly held stock options include 30,000 shares from the new grant, plus existing options over 100,000 shares, 80,000 shares, and two small positions of 4 shares each, all referencing Tenax Therapeutics common stock.

What are the terms of the new 30,000-share stock option reported for TENX?

The new 30,000-share stock option for Tenax Therapeutics common stock has an exercise price of $13.30 per share, becomes exercisable on January 9, 2027, and has an expiration date of January 9, 2036.

Does June Sherie Almenoff hold any Tenax Therapeutics common shares indirectly?

Yes. The Form 4 shows 1,993 shares of Tenax Therapeutics common stock held indirectly through Meadowlark Management, LLC. The filing states that Almenoff disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.

Is June Sherie Almenoff a 10% owner of Tenax Therapeutics?

No. The Form 4 identifies June Sherie Almenoff as a director of Tenax Therapeutics and does not mark her as a 10% owner. The relationship box is checked only for director status.

Were any Tenax Therapeutics shares sold in this Form 4 filing?

No sales are reported. The filing shows a stock option grant coded "A" for acquisition of 30,000 derivative securities and lists existing option and share holdings, without any disposition transactions.